Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals’ (ASX:RCE) R327 demonstrates notable bacterial reduction activity against the life-threatening STD, N. gonorrhoeae
- A study was conducted by the Murdoch Children’s Research Institute to test the efficacy of R327 on mouse vaginal infection models
- Mice were inoculated vaginally with N. gonorrhoea and after receiving R327 over three days at an IV dose of 1000mg/kg bacterial shedding was significant
- Recce has also announced that the Australian Government has granted an Advanced Overseas Finding of $43.7 million for the company’s synthetic antibiotic R&D expenditures, administered by AusIndustry
- RCE shares last traded at 46.5 cents
Recce Pharmaceuticals’ (ASX:RCE) lead anti-infective drug, R327 has shown significant bacterial reduction against the life-threatening sexually transmitted disease (STD), Neisseria gonorrhoeae (N. gonorrhoeae).
A study by the Murdoch Children’s Research Institute tested R327’s efficacy on a mouse vaginal infection model. Ten mice were inoculated vaginally with N. gonorrhoeae.
Administered twice daily through an intravenous bolus dose of 1000 milligrams per kilogram (mg/kg), R327 achieved a 99.99 per cent reduction in bacterial shedding within just three days.
N. gonorrhoeae is a top-priority pathogen on the World Health Organisation’s list due to the increasing prevalence of antibiotic-resistant strains and its potential for severe health consequences.
“The need for a new class of anti-infectives could not be greater, especially against a lethal pathogen such as N. gonorrhoea,” RCE CEO James Graham said.
“The data from this study, along with the previous findings, emphasise the capability of R327 to demonstrate broad spectrum activity against antibiotic-resistant bacteria, even with repeated use.”
Recce awarded $43.7m
Also today, Recce has announced that the Australian Government has granted an Advanced Overseas Finding of $43.7 million for the company’s synthetic antibiotic research and development (R&D) expenditures, administered by AusIndustry.
This funding is recognised as one of the largest ever awarded in Australian history.
The acknowledgment of the company’s R&D activities as being of national interest is highlighted in this funding, further complementing RCE’s recent capital raise of $11 million.
“We would like to express our gratitude to AusIndustry and the Department of Industry, Innovation, and Science for their ongoing crucial support in advancing science and its practical applications, particularly in the development of innovative therapies with a global impact,” Mr Graham said.
“This development is a further endorsement of the company’s growth potential and secures our caveat-free R&D funding long-term.”
RCE shares last traded at 46.5 cents.
